TSX:CTX - Post Discussion
Post by
Possibleidiot01 on Aug 09, 2024 5:43pm
Mathieu Martin - Stocks and Stones
-
Crescita Therapeutics (TSX: CTX) is firing on all cylinders. In the span of a week, CTX announced a distribution agreement for a new medical aesthetic product, a new long-term manufacturing deal for sanitary products that could be worth up to $6 million in annual revenues, and an amended contract manufacturing agreement with a large customer worth a minimum of US $2.5 million per year for four years. Those announcements appear significant for a company that reported $17.5 million in revenue last year. Even after a 17% increase in share price in July, the market gives the company very little credit. The enterprise value is a mere $2.3 million after backing out $9.5 million of net cash on the balance sheet.
Be the first to comment on this post